Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Coherus BioSciences, Inc.

< Previous 1 2 Next >
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences to Participate at Upcoming November Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Completes Surface Oncology Acquisition
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences to Participate at Upcoming September Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Prices Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus Announces Proposed Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
Tickers CHRS
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.